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• The purpose of this experiment was to see the effect of ATP on 
NF-kB activity by performing western blotting. 
• It was suggested that the decrease in the amount of ATP is shown 
by the thickening of bands on AMP activated protein kinase at 
Thr-172. The decrease in ATP results in less apoptosis. 
• The thinning of bands in figure 2 by the co-treatment of BAY-
876 with MinB and Met indicated strong inhibition of NF-kB. 
By inhibiting the amount of glucose transport, the cell isn’t able 
to get the proper nutrients it needs. 
• To summarize, metformin and the metformin like compound had 
a significant effect on AMPK-p in the two different cell lines. 
Furthermore, this experiment successfully made use of the 
symbolic relationship between ATP production and NF-kB. 
• When there is ATP deficiency and inhibition of glucose 
transport, there is an inactivation of NF-kB. 
• In regards to the society, a decrease in the amount of ATP, 
through the symbiotic mechanism between decreased 
phosphorylated sites on transcription factor and more apoptosis, 
offers a more palatable way for individuals looking to reduce the 
number of cancer “bad” cells.
• When future researchers open up to testing different cancer cell 
lines with different drugs with this same mechanism, there are 
high hopes that humans and perhaps other species as well, can 
benefit. Future research can be conducted to measure cytokine 
production with ELISA assay. 
In both ovarian cancer cell lines in all four gels, ATP deficiency plus 
inhibition of glucose transport lead to a significant decrease in band 
size. In figures 1 and 2, Metformin and MinB treatment lead to thicker 
bands of AMPK-p. There wasn’t a significant change in band size 
when Met, MinB, or BAY-876 was tested on RelA p65. Co-treatment 
of Met or MinB with Bay-876 showed the thickest bands compared to 
all other treated bands in figure 1. In figure 2, co-treatment of Met or 
MinB with BAY-876 showed a significant decrease in band size. 
I would like to express my deep gratitude to Dr. Fang from Massey 
Cancer Center for providing me the opportunity and resources to 
conduct this research project.
• The research design of this study was experimental as it studied the 
relationship between ATP production and NF-kB activity.
• Sodium dodecyl sulfate (SDS) was used to denature the protein 
and provide equal mass to charge ratio so as to allow the protein to 
move constantly through the gel based on its molecular weight. 
The SDS caused proteins to denature and separate from each other 
(excluding covalent cross-linking). SDS gel was prepared by first 
preparing resolving gel and placing that gel into the prepared glass 
ware. The gel solutions ordered were from National Diagnostics in 
Atlanta, Georgia. Once membranes were labeled, a black sponge 
was placed on top of the white paper which is on top of the gel and 
then the apparatus was closed. Approximately 92 volts was run 
through the membrane overnight. In the morning, the membranes 
were placed in primary and then secondary antibodies. All 
antibodies were ordered from Cell Signaling Technology located in 
Danvers, MA. For the last step, the membranes were put in a white 
carrier. The last step is called luminescence. During this step, an 
ECL reaction takes place in which light induces the signal in a 
Amersham Hyperfilm film (BioRid, Plymouth, MI). The signal is 
both light and time sensitive so too much signal will have a 
negative effect on the data sample collected. Running of the gel 
was performed on medical film processor SRX-101A (Konica 
Minolta Medical & Graphic Inc., Wayne, NJ.) The film was then 
analyzed.
NF-kB is a transcription factor involved in cancer cell growth and survival. 
The activation of NF-kB can be assessed by monitoring phosphorylation of 
RelA p65 at Ser-536, which is a surrogate of the NF-kB transcription factor 
activation. The objective of this study was to determine if the loss of ATP 
leads to NF-kB deficiency and thus, apoptotic cell death of “bad” cells in 
ovarian cancer cells. The independent variables were metformin (Met), an 
anti-diabetic medicine, another compound MinB functionally similar to Met 
and a glucose transporter inhibitor BAY-876. The dependent variables were 
the resulting effect of Met and MinB on phosphorylated AMPK at Thr-172 
(marker of ATP loss) and RelA p65 ar Ser-536 (marker of NF-kB 
activation). In each experiment, AMPK and RelA phosphorylation were 
tested by treatment of ovarian cancer cell lines with Met, MinB, BAY-876, 
Met+BAY-876, MinB+BAY-876. Western blotting was performed to 
determine the phosphorylation levels of AMPK and RelA p65. For two 
gels, the process was repeated. In each gel, Met or MinB treatment leads to 
thicker bands of AMPK-p, indicating decrease in cellular ATP levels 
following treatments. The effect of Met, MinB, or BAY-876 on RelA p65 
was limited. However, co-treatment of Met or MinB with BAY-876 caused 
strong inhibition of NF-kB, as reflected by reduction in RelA p65-p. These 
results suggested that ATP deficiency together with inhibition of glucose 
transport cause inactivation of NK-kB. 
Figure 3. Ovarian Cancer 
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